Activation of the HGF/c-Met axis is also one of the causes of resistance to Renvastinib in patients (76).Activation of this pathway resulted in the following resistance effects: HGF attenuated the anti-proliferative, pro-apoptotic, and anti-invasive functions of lenvatinib in HCC cells with high c-MET expression (77). The gene discussed is MET; the disease is hepatocellular carcinoma.